Evidence map›Paper›PMID 39559560›Full record

ArticleMolecular therapy. Methods & clinical development2024

Insights in AAV-mediated antigen-specific immunity and a strategy for AAV vaccine dose reduction through AAV-extracellular vesicle association.

Ester Molina, Marcos Tejero, Ozgun Firat Duzenli, Hisae Kuoch, Colin Caine, Karina Krotova, Michael Paulaitis, George Aslanidi

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Molecular therapy. Methods & clinical development, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Review
  5. Review
  6. Extracellular Vesicle-Based Drug Delivery Systems in Cancer Therapy.International journal of molecular sciences · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ester MolinaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Marcos TejeroThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Ozgun Firat DuzenliThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Hisae KuochThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Colin CaineThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Karina KrotovaThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.
Michael PaulaitisDepartment of Ophthalmology, Center for Nanomedicine at the Wilmer Eye Institute, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
George AslanidiThe Hormel Institute, University of Minnesota, Austin, MN 55912, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We previously showed therapeutic advantages of using a capsid-modified and encoded antigen-optimized AAV-based cancer vaccine to initiate strong antigen-specific immune responses and increase survival in a syngeneic mouse model of melanoma. In this study, we further explore AAV vaccine dose reduction and possible mechanisms of the immune response. Immunization with extracellular vesicle (EV)-associated AAV6-S663V encoded ovalbumin (OVA) or tyrosinase-related protein 1 (TRP-1) induced significantly higher levels of antigen-specific CD8

Indexed as

adeno-associated virusantigen-specific T cellcancer vaccinedendritic cellextracellular vesiclesprotective immune response

Identifiers

PMID39559560
PMCPMC11570487

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.